Bcl-2 clearance: Optimising outcomes in follicular non-Hodgkin’s lymphoma

Bone Marrow Transplantation

Volumn 29, Issue , 2002, Pages S14-S17

  Berinstein, N L ^a   Buckstein, R ^a   Imrie, K ^a   Spaner, D ^a   Mangel, J ^a   Tompkins, K ^a   Pennell, N ^a   Reis, M ^a   Pavlin, P ^a   Lima, A ^a   Couvadia, A ^a   Robinson, J ^a   Richardson, P ^a  

^a Women's College Health Centre   (Canada)

Author keywords

bcl 2; Follicular lymphoma; In vivo purging; Rituximab; Stem cell transplantation

Indexed keywords

EID: 0036190626     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703297     Document Type: Article

References (26)

1. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas
2. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin’s lymphoma
3. Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stages III and IV low grade non-Hodgkin’s lymphoma. Preliminary results from a prospective randomized phase III clinical trial in 381 patients
4. All advanced stage non-Hodgkin’s lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
5. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma
6. BCL2 translocation frequency rises with age in humans
7. BCL-2 family: Regulators of cell death
8. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
9. The clinical significance of molecular response in indolent follicular lymphomas
10. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: Update of the MDACC series
11. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
12. Clearing of cells bearing the bcl-2 [t(14; 18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
13. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow
14. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
15. Purging peripheral blood progenitor cell grafts from lymphoma cells: Quantitative comparison of immunomagnetic CD34+ selection systems
16. Autologous stem-cell transplantation for non-Hodgkin’s lymphomas: The role of graft purging and radiotherapy posttransplantation - Results of a retrospective analysis on 120 patients autografted in a single institution
17. Investigation of monoclonal antibody therapy with conventional and high-dose treatment: Current clinical trials
18. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
19. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
20. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
21. MabThera (rituximab) plus CHOP is superior to chop alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial
22. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
23. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
24. Stem cell function and engraftment is not affected by ’in vivo purging’ with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin’s lymphoma
25. In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients (pts)
26. Efficiency of in vivo purging with rituximab followed by high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation (PBSCT) in B-cell non-Hodgkin’s lymphomas (NHL). A single institution study